Molsidomine

From WikiProjectMed
Jump to navigation Jump to search
Molsidomine
Clinical data
Trade namesCorvasal, Corvaton, Molsidain, Molsidolat, others
AHFS/Drugs.comInternational Drug Names
Routes of
administration		By mouth (tablets), intravenous infusion
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability44–59%
Protein binding3–11%
MetabolismHydrolysis
MetabolitesLinsidomine
Elimination half-life1–2 hrs (linsidomine)
Excretion>90% renal
Identifiers
  • 1-Ethoxy-N-(3-morpholino-5-oxadiazol-3-iumyl)methanimidate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.042.902 Edit this at Wikidata
Chemical and physical data
FormulaC9H14N4O4
Molar mass242.235 g·mol−1
3D model (JSmol)
Melting point140 to 141 °C (284 to 286 °F)
  • [O-]C(OCC)=Nc2on[n+](N1CCOCC1)c2
  • InChI=1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3 checkY
  • Key:XLFWDASMENKTKL-UHFFFAOYSA-N checkY

Molsidomine (trade names Corvasal, Corvaton and many others) is an orally active, long acting vasodilating drug used to treat angina pectoris. Molsidomine is metabolized in the liver to the active metabolite linsidomine. Linsidomine is an unstable compound that releases nitric oxide (NO) upon decay as the actual vasodilating compound.[1]

Medical uses

Molsidomine is used for the prevention and long-term treatment of stable and unstable angina pectoris, with or without left heart failure. It is also used to treat angina in the context of an acute myocardial infarction.[2][3]

Contraindications

The drug must not be used in patients with acute cardiac arrest or severe hypotension (low blood pressure), during lactation, and in combination with PDE5 inhibitors such as sildenafil.[2][3]

Side effects

The most common adverse effects are headache, which occurs in 10–25% of patients, and low blood pressure. Side effects occurring in fewer than 1% of patients include dizziness, nausea, reflex tachycardia (fast heartbeat), hypersensitivity reactions, as well as thrombocytopenia (low blood platelet count) in rare cases.[2][3]

Interactions

The blood pressure lowering effect of molsidomine can be amplified significantly by PDE5 inhibitors, potentially leading to fainting or myocardial infarction, and to a lesser extent by other antihypertensive drugs such as beta blockers, calcium channel blockers, or other nitrovasodilators. Ergolines can antagonise the effects of molsidomine.[2][3]

Pharmacology

Mechanism of action

Further information: Biological functions of nitric oxide

Molsidomine belongs to the drug class of nitrovasodilators. It releases NO, which acts as a gaseous signaling molecule, relaxing the smooth muscles of blood vessels.[4][5]

Pharmacokinetics

The substance is quickly and almost completely (>90%) absorbed from the gut. Molsidomine is a prodrug that is hydrolysed to linsidomine (SIN-1) in the liver via first-pass effect, which subsequently releases NO. 44–59% of molsidomine reach the bloodstream in unchanged form, 3–11% of which are bound to plasma proteins. Both molsidomine and linsidomine reach their highest concentrations in the blood plasma after one to two hours. Linsidomine has a biological half-life of one to two hours. More than 90% are excreted via the kidney.[2][4]

NO release from molsidomine[4]

Chemistry

The mesoionic structure of molsidomine

Molsidomine and linsidomine are sydnone imines, a class of mesoionic heterocyclic aromatic chemical compounds. Molsidomine melts at 140–141 °C (284–286 °F), is freely soluble in chloroform, soluble in aqueous hydrochloric acid, ethanol, ethyl acetate and methanol, sparingly soluble in water and acetone, and very slightly soluble in diethyl ether and petroleum ether. It is stable in aqueous solutions at pH 5–7, but not in alkaline solutions. Its absorption maximum is in the near ultraviolet, at 326 nm, in chloroform. The substance is sensitive to ultraviolet light at wavelengths shorter than 320 nm.[3]

Synthesis

Thieme Synthesis:[6] Patents:[7]

Its synthesis starts by reacting 1-aminomorpholine with formaldehyde and hydrogen cyanide to give 2. Nitrosation gives the N-nitroso analog (3) which cyclizes to the Linsidomine (4) on treatment with anhydrous acid. Formation of the ethyl urethane is then made possible by reacting linsidomine with ethyl chloroformate.

Also see a related structure called Ciclosidomine.

History

The substance was first synthesised at Takeda in 1970. Its antihypertensive and vasodilating properties were discovered the same year.[8]

References

  1. ^ Rosenkranz B, Winkelmann BR, Parnham MJ (May 1996). "Clinical pharmacokinetics of molsidomine". Clinical Pharmacokinetics. 30 (5): 372–84. doi:10.2165/00003088-199630050-00004. PMID 8743336.
  2. ^ a b c d e Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. 2018. Molsidolat 4 mg-Tabletten. ISBN 978-3-85200-196-8.
  3. ^ a b c d e Dinnendahl V, Fricke U, eds. (2010). Arzneistoff-Profile (in German). Vol. 7 (24 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. Molsidomin. ISBN 978-3-7741-9846-3.
  4. ^ a b c Mutschler E, Schäfer-Korting M (2001). Arzneimittelwirkungen (in German) (8 ed.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. p. 558. ISBN 978-3-8047-1763-3.
  5. ^ Stryer L (1995). Biochemistry (4th ed.). W.H. Freeman and Company. p. 732. ISBN 978-0-7167-2009-6.
  6. ^ Chemical and Pharmaceutical Bulletin 19(1), 72-79, 1971-01-25.
  7. ^ DE1695897 idem K Masuda & Y Imashiro, U.S. patent 3,769,283 & US3812128 (1973 & 1974 to Takeda Pharmaceutical Co Ltd).
  8. ^ Müller-Jahncke WB, Friedrich C, Meyer U (2005-01-01). Arzneimittelgeschichte (2nd ed.). Stuttgart: Wiss. Verl.-Ges. p. 163. ISBN 9783804721135.
Retrieved from "https://mdwiki.org/wiki/Molsidomine"